Skip to menu Skip to content Skip to footer

2022

Journal Article

The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective

Lee, Sze Ting, Emmett, Louise M., Pattison, David A., Hofman, Michael S., Bailey, Dale L., Latter, Melissa J., Francis, Roslyn J. and Scott, Andrew M. (2022). The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective. Journal of Nuclear Medicine, 63 (6), 819-822. doi: 10.2967/jnumed.122.263996

The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective

2022

Conference Publication

TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins.

TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)

2022

Conference Publication

A prospective, multi-centre trial of FET-PET In Glioblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing program

Koh, E. S., Moore, A., Francis, R. J., Ebert, M. A., Gan, H. K., Lee, S. T., Lau, E., Rossi, A., Grose, A., Ng, S. P., Barnes, E. H., Moffat, B. A., Scott, F. E., Adda, L., Foroudi, F., Nowak, A. K., Bailey, D. L., Back, M., Lourenco, R. De Abreu and Scott, A. M. (2022). A prospective, multi-centre trial of FET-PET In Glioblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing program. HOBOKEN: WILEY.

A prospective, multi-centre trial of FET-PET In Glioblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing program

2022

Journal Article

Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: a case report and review of the literature

Youn, Paul, Francis, Roslyn J., Preston, Henry and Lake, Fiona (2022). Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: a case report and review of the literature. Respirology Case Reports, 10 (5) e0949. doi: 10.1002/rcr2.949

Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: a case report and review of the literature

2022

Journal Article

Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)

Lam, Virginie, Clarnette, Roger, Francis, Roslyn, Bynevelt, Michael, Watts, Gerald, Flicker, Leon, Orr, Carolyn F, Loh, Poh, Lautenschlager, Nicola, Reid, Christopher M., Foster, Jonathan K., Dhaliwal, Satvinder S., Robinson, Suzanne, Corti, Emily, Vaccarezza, Mauro, Horgan, Ben, Takechi, Ryusuke and Mamo, John (2022). Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open, 12 (2) e058826, e058826. doi: 10.1136/bmjopen-2021-058826

Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)

2022

Conference Publication

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

2022

Conference Publication

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

2022

Journal Article

Imaging in pleural mesothelioma: a review of the 15th International Conference of the International Mesothelioma Interest Group

Armato, Samuel G., Nowak, Anna K., Francis, Roslyn J., Katz, Sharyn I., Kholmatov, Manizha, Blyth, Kevin G., Gudmundsson, Eyjolfur, Kidd, Andrew C. and Gill, Ritu R. (2022). Imaging in pleural mesothelioma: a review of the 15th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 164, 76-83. doi: 10.1016/j.lungcan.2021.12.008

Imaging in pleural mesothelioma: a review of the 15th International Conference of the International Mesothelioma Interest Group

2022

Journal Article

The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial

Bellinge, Jamie W., Francis, Roslyn J., Lee, Sing C., Bondonno, Nicola P., Sim, Marc, Lewis, Joshua R., Watts, Gerald F. and Schultz, Carl J. (2022). The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial. The American Journal of Clinical Nutrition, 115 (1), 45-52. doi: 10.1093/ajcn/nqab306

The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial

2021

Journal Article

18F-sodium fluoride positron emission tomography activity predicts the development of new coronary artery calcifications

Bellinge, Jamie W., Francis, Roslyn J., Lee, Sing Ching, Phillips, Michael, Rajwani, Adil, Lewis, Joshua R., Watts, Gerald F. and Schultz, Carl J. (2021). 18F-sodium fluoride positron emission tomography activity predicts the development of new coronary artery calcifications. Arteriosclerosis, Thrombosis, and Vascular Biology, 41 (1), 534-541. doi: 10.1161/ATVBAHA.120.315364

18F-sodium fluoride positron emission tomography activity predicts the development of new coronary artery calcifications

2021

Journal Article

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Emmett, Louise, Subramaniam, Shalini, Joshua, Anthony M., Crumbaker, Megan, Martin, Andrew, Zhang, Alison Y., Rana, Nisha, Langford, Ailsa, Mitchell, Jenna, Yip, Sonia, Francis, Roslyn, Hofman, Michael S., Sandhu, Shahneen, Azad, Arun, Gedye, Craig, McJannett, Margaret, Stockler, Martin R. and Davis, Ian D. (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128 (5), 642-651. doi: 10.1111/bju.15491

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

2021

Journal Article

Radiomics for identification and prediction in metastatic prostate cancer: a review of studies

Kendrick, Jake, Francis, Roslyn, Hassan, Ghulam Mubashar, Rowshanfarzad, Pejman, Jeraj, Robert, Kasisi, Collin, Rusanov, Branimir and Ebert, Martin (2021). Radiomics for identification and prediction in metastatic prostate cancer: a review of studies. Frontiers in Oncology, 11 (771787) 771787, 1-22. doi: 10.3389/fonc.2021.771787

Radiomics for identification and prediction in metastatic prostate cancer: a review of studies

2021

Journal Article

Imaging inflammation in patients and animals: focus on PET imaging the vulnerable plaque

Bartlett, Benjamin, Ludewick, Herbert P., Lee, Silvia, Verma, Shipra, Francis, Roslyn J. and Dwivedi, Girish (2021). Imaging inflammation in patients and animals: focus on PET imaging the vulnerable plaque. Cells, 10 (10) 2573, 2573. doi: 10.3390/cells10102573

Imaging inflammation in patients and animals: focus on PET imaging the vulnerable plaque

2021

Journal Article

Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype

Lam, Virginie, Takechi, Ryusuke, Hackett, Mark J., Francis, Roslyn, Bynevelt, Michael, Celliers, Liesl M., Nesbit, Michael, Mamsa, Somayra, Arfuso, Frank, Das, Sukanya, Koentgen, Frank, Hagan, Maree, Codd, Lincoln, Richardson, Kirsty, O’Mara, Brenton, Scharli, Rainer K., Morandeau, Laurence, Gauntlett, Jonathan, Leatherday, Christopher, Boucek, Jan and Mamo, John C.L. (2021). Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype. PLoS Biology, 19 (9) e3001358, 1-26. doi: 10.1371/journal.pbio.3001358

Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype

2021

Journal Article

Impact of COVID-19 pandemic on cardiovascular testing in Asia: the IAEA INCAPS-COVID Study

Kudo, Takashi, Lahey, Ryan, Hirschfeld, Cole B., Williams, Michelle C., Lu, Bin, Alasnag, Mirvat, Bhatia, Mona, Henry Bom, Hee-Seung, Dautov, Tairkhan, Fazel, Reza, Karthikeyan, Ganesan, Keng, Felix Y.J., Rubinshtein, Ronen, Better, Nathan, Cerci, Rodrigo Julio, Dorbala, Sharmila, Raggi, Paolo, Shaw, Leslee J., Villines, Todd C., Vitola, João V., Choi, Andrew D., Malkovskiy, Eli, Goebel, Benjamin, Cohen, Yosef A., Randazzo, Michael, Pascual, Thomas N.B., Pynda, Yaroslav, Dondi, Maurizio, Paez, Diana ... Nguyen, Xuan Canh (2021). Impact of COVID-19 pandemic on cardiovascular testing in Asia: the IAEA INCAPS-COVID Study. JACC: Asia, 1 (2), 187-199. doi: 10.1016/j.jacasi.2021.06.002

Impact of COVID-19 pandemic on cardiovascular testing in Asia: the IAEA INCAPS-COVID Study

2021

Journal Article

Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment

Barry, Nathaniel, Rowshanfarzad, Pejman, Francis, Roslyn J., Nowak, Anna K. and Ebert, Martin A. (2021). Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment. Physical and Engineering Sciences in Medicine, 44 (4), 1131-1140. doi: 10.1007/s13246-021-01049-4

Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment

2021

Journal Article

The australasian radiopharmaceutical trials network: Clinical trials, evidence, and opportunity

Francis, Roslyn J., Bailey, Dale L., Hofman, Michael S. and Scott, Andrew M. (2021). The australasian radiopharmaceutical trials network: Clinical trials, evidence, and opportunity. Journal of Nuclear Medicine, 62 (6), 755-756. doi: 10.2967/jnumed.120.258152

The australasian radiopharmaceutical trials network: Clinical trials, evidence, and opportunity

2021

Journal Article

Repeatability of quantitative 18F-FET PET in glioblastoma

Ferjančič, Peter, Ebert, Martin A., Francis, Roslyn, Nowak, Anna K. and Jeraj, Robert (2021). Repeatability of quantitative 18F-FET PET in glioblastoma. Biomedical Physics and Engineering Express, 7 (3) 035020, 1-10. doi: 10.1088/2057-1976/abfae9

Repeatability of quantitative 18F-FET PET in glioblastoma

2021

Journal Article

UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Dhiantravan, Nattakorn, Emmett, Louise, Joshua, Anthony M., Pattison, David A., Francis, Roslyn J., Williams, Scott, Sandhu, Shahneen, Davis, Ian D., Vela, Ian, Neha, Nitika, Bressel, Mathias, Murphy, Declan G., Hofman, Michael S. and Azad, Arun A. (2021). UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol). BJU International, 128 (3) bju.15384, 331-342. doi: 10.1111/bju.15384

UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

2021

Journal Article

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

de Feria Cardet, Rafael E., Hofman, Michael S., Segard, Tatiana, Yim, Jackie, Williams, Scott, Francis, Roslyn J., Frydenberg, Mark, Lawrentschuk, Nathan, Murphy, Declan G. and De Abreu Lourenco, Richard (2021). Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. European Urology, 79 (3), 413-418. doi: 10.1016/j.eururo.2020.11.043

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial